Join us for an informative webinar exploring KYGEVVI™ (doxecitine and doxribtimine), the first FDA-approved treatment for thymidine kinase 2 deficiency (TK2d) in adults and pediatric patients with an age of symptom onset on or before 12 years.
This session will cover:
- The basics of TK2d, including its genetic cause, symptoms, and how it is diagnosed
- The impact of TK2d on patients and families
- An overview of KYGEVVI, including how it works and who may be eligible for treatment
- Important safety information and what to expect with therapy
For full prescribing information and important safety details, please visit https://www.kygevvi.com/.
